Creative Touch Permanent Makeup and Aesthetics

Malonyl-CoA is a small three-carbon intermediate produced when acetyl-CoA carboxylase (ACC) attaches a carboxyl group to acetyl-CoA – a reaction requiring biotin as cofactor and ATP as energy source. Its cellular concentration is a real-time gauge of glucose and insulin status: it rises when carbohydrate and insulin are elevated, and falls during fasting, exercise, or carbohydrate restriction. This single concentration change serves two structurally distinct functions depending on which ACC isoform produced it: ACC2-derived malonyl-CoA, generated at the outer mitochondrial membrane, allosterically inhibits CPT-1 and suppresses fat oxidation; ACC1-derived malonyl-CoA, in the cytosol, is consumed in fatty acid synthesis and in every step of the ELOVL elongation cycles that produce the very long-chain ceramides the skin barrier depends upon. These two pools are functionally separate – a distinction with direct implications for how dietary and metabolic state affects both fuel selection and epidermal lipid quality.

Malonyl-CoA occupies a small and precisely positioned place in cellular biochemistry. It is a three-carbon dicarboxylic acid thioester – essentially acetyl-CoA with an additional carboxyl group – produced by acetyl-CoA carboxylase (ACC) through the ATP-dependent carboxylation of acetyl-CoA. Its concentration in cells is not maintained at a fixed set point; it rises and falls in close correspondence with metabolic state, making it a genuine metabolic signal rather than merely a metabolic intermediate. When malonyl-CoA is elevated, two things happen simultaneously: the cell suppresses fat oxidation (via CPT-1 inhibition) and accelerates fatty acid construction (as the substrate for FAS and ELOVL elongation). When it is low, fat oxidation is released and lipid synthesis from glucose is constrained. A single metabolite governing both the brake on fat burning and the substrate for fat building – its dual function is why the enzyme that produces it – and the regulatory machinery that controls that enzyme – is the necessary starting point. ^[11]

Malonyl-CoA has exactly one biosynthetic source: the enzyme acetyl-CoA carboxylase (ACC). It has no alternative synthesis pathway and no salvage route – if ACC is active, malonyl-CoA rises; if ACC is inhibited, malonyl-CoA falls. Every physiological and pharmacological intervention that changes malonyl-CoA concentration – exercise, fasting, insulin, metformin, AMPK activation – does so by changing ACC’s activity, directly or indirectly. Understanding the metabolite therefore requires understanding the enzyme that produces it, because ACC is not merely a gateway to malonyl-CoA; it is the regulatory mechanism.

Acetyl-CoA Carboxylase (ACC)

Acetyl-CoA carboxylase is a large biotin-dependent multidomain enzyme (~250 kDa per subunit) built around three conserved functional components – and as the sole enzymatic gateway to both of malonyl-CoA’s functions, its activity state is the proximate molecular determinant of whether a cell is primed toward fat synthesis and fat-oxidation suppression, or not.

Structure and catalytic mechanism. ACC is a large multidomain enzyme (~250 kDa per subunit) built around three conserved functional components. ^[10] The biotin carboxylase (BC) domain uses ATP to carboxylate the biotin prosthetic group, with bicarbonate as the carbon donor. The biotin carboxyl carrier protein (BCCP) domain carries biotin covalently attached to a lysine residue and physically shuttles the activated carboxyl group between the BC and CT active sites. The carboxyl transferase (CT) domain completes the reaction by transferring the carboxyl group from carboxybiotin to acetyl-CoA, forming malonyl-CoA. The reaction is irreversible under physiological conditions, committing the carbon to lipid chemistry; the only route back from malonyl-CoA to acetyl-CoA is through malonyl-CoA decarboxylase (MCD).

Allosteric regulation. ACC is subject to opposing allosteric inputs from two metabolite signals. Citrate – the TCA cycle intermediate exported from the mitochondria to serve as the cytosolic carbon shuttle – allosterically activates ACC by promoting its polymerisation from inactive dimers into higher-order active filaments. ^[6] This represents a coherent feed-forward signal: elevated mitochondrial carbon export in the glucose-replete state activates the enzyme that diverts that carbon into lipid synthesis. The physiological significance of citrate-induced polymerisation alone has been questioned, since concentrations required for activation are higher than typical cytosolic levels; however, the scaffold protein MIG12 substantially lowers the citrate concentration required for half-maximal ACC activation to approximately 0.2 mM – within the physiological range. ^[6] Long-chain acyl-CoAs – particularly palmitoyl- CoA – exert opposing product-feedback inhibition: as fatty acid synthesis products accumulate, they allosterically suppress the enzyme that initiated their production. ^[10]

Covalent regulation. Phosphorylation and dephosphorylation of ACC are the dominant acute regulatory mechanisms, mediated by opposing kinase and phosphatase inputs. AMPK – activated by rising AMP:ATP ratios during exercise, fasting, or caloric restriction – inactivates both ACC1 at Ser79 and ACC2 at Ser221 (human numbering; mouse ACC2 uses Ser212) through direct phosphorylation. PKA (activated by glucagon and elevated cAMP in the fasted liver) phosphorylates and inactivates ACC1 through a distinct site. ^[10] In the opposing direction, insulin activates protein phosphatase 2A (PP2A), which dephosphorylates the inhibitory sites on ACC and restores activity – a mechanism confirmed in isolated hepatocytes, where insulin exposure produced a marked decrease in ACC phosphorylation coincident with its activation. ^[14] Insulin simultaneously suppresses AMPK activity and, through SREBP-1c, transcriptionally upregulates ACC1 expression – meaning a post-meal insulin rise promotes ACC activation through three parallel routes: phosphatase-driven dephosphorylation, AMPK suppression, and increased enzyme abundance.

ACC as the regulatory chokepoint. The phosphorylation state of ACC’s Ser79/Ser221 regulatory sites is the single convergence point for every intervention that shifts cellular malonyl-CoA concentration – and therefore every intervention that influences the fuel-switching blockade or ceramide elongation substrate supply described in this entity. Aerobic exercise, carbohydrate restriction, intermittent fasting, metformin, and adiponectin signalling all reduce malonyl-CoA through ACC inhibition as their final common molecular step. This is why these interventions improve metabolic flexibility through the same mechanism rather than through parallel independent pathways – they are different upstream inputs arriving at the same gate.

Synthesis: Two Enzymes, Two Compartments, Two Functions

ACC1 is a cytosolic enzyme, the predominant isoform in lipogenic tissues – liver, adipose, mammary gland, and skin. The malonyl-CoA it generates enters either fatty acid synthase (FAS) for de novo palmitate production, or the ELOVL elongation machinery for extension of existing fatty acid chains. ACC1 is transcriptionally regulated by SREBP-1c, the sterol regulatory element-binding protein activated by insulin and carbohydrate excess, meaning its expression rises with sustained carbohydrate feeding. In mice, ACC1 knockout is embryonic lethal – de novo fatty acid synthesis is essential for foetal development and cannot be dispensed with. ^[13]

ACC2 is localised to the outer mitochondrial membrane via a 20-amino-acid hydrophobic N-terminal extension absent from ACC1. This physical positioning at the mitochondrial surface means the malonyl-CoA it produces sits precisely where CPT-1 is embedded – allowing highly localised, compartmentalised inhibition without necessarily elevating cytosolic malonyl-CoA for lipogenesis. In mice, ACC2 knockout produces normal growth and fertility but dramatically increased fatty acid oxidation, reduced fat accumulation, and near-complete protection against high-fat and high-fat/high-carbohydrate diet-induced obesity and insulin resistance – without altering CPT-1 expression levels. The metabolic protection arose purely from the absence of CPT-1-inhibiting malonyl-CoA. ^[1]

Clinical Pearl The ACC1/ACC2 compartmentalisation is experimentally established, not inferred. The ACC2 knockout mouse (PNAS, 2003) is the clean proof: removing the CPT-1-inhibiting pool of malonyl-CoA (ACC2) protects against metabolic disease while preserving normal lipid synthesis (ACC1 intact). This validates the specific mechanistic claim that it is the ACC2→malonyl-CoA→CPT-1 axis that creates the fuel-switching block in metabolic inflexibility – not malonyl-CoA in general.

The degree of pool separation in human tissues is not absolute. At very high malonyl-CoA concentrations – as may occur with severe carbohydrate excess or insulin resistance – the cytosolic ACC1-derived pool can overspill and also inhibit CPT-1. The functional separation is concentration-dependent rather than absolute, but under physiological conditions the spatial localisation of ACC2 at the mitochondria is the dominant mechanism of CPT-1 regulation. ^[11]

The CPT-1 Brake: Closing the Randle Cycle Loop

The glucose→fat suppression direction of the Randle Cycle is carried out through this molecule. When glucose is elevated and insulin is secreted, glycolysis generates pyruvate; PDC commits it to mitochondrial acetyl-CoA; citrate is exported to the cytosol; ACLY cleaves it back to acetyl-CoA; ACC2 carboxylates it to malonyl-CoA at the outer mitochondrial membrane; malonyl-CoA binds the C-terminal allosteric site on CPT-1 and suppresses long-chain fatty acid transport into the mitochondrial matrix. Fat oxidation falls. The malonyl-CoA/CPT-1 step is where the glucose-derived signal physically blocks the fatty acid pathway. ^[5]

The potency and reversibility of this inhibition differ between tissues. Muscle CPT1B – the isoform expressed in cardiac and skeletal muscle – has a malonyl-CoA sensitivity approximately 30–100 times greater than the liver’s CPT1A, with half-maximal inhibition at approximately 0.02 μM versus 2 μM. In practice, this means that even modest rises in muscle malonyl-CoA following carbohydrate intake effectively shut down muscle fat oxidation, whilst the liver retains partial fat oxidation capacity across a wider range of malonyl-CoA concentrations. ^[5]

Malonyl-CoA’s inhibition of CPT-1 is directly implicated in the accumulation of lipotoxic intermediates – diacylglycerol (DAG) and ceramides – that are the operative mechanism of lipid-induced insulin resistance. When CPT-1 is blocked and incoming dietary fat cannot enter the mitochondria for oxidation, it is rerouted toward esterification in the cytosol, eventually generating DAG, which activates protein kinase C epsilon (PKCε) in muscle and liver, impairing insulin receptor substrate-1 (IRS-1) signalling. This mechanism is the subject of the dedicated Diacylglycerol (DAG) entity.

The Fatty Acid Synthesis Role: Building from the Ground Up

ACC1-derived malonyl-CoA is the obligate two-carbon donor for all de novo fatty acid elongation. Fatty acid synthase (FAS) uses one acetyl-CoA as the primer and seven successive malonyl-CoA molecules to assemble palmitate (C16:0) through repeated Claisen condensation reactions. Each condensation step adds two carbons, releases CO₂ (reversing the ACC carboxylation energetically), and requires NADPH for reduction. The net reaction for palmitate synthesis requires 8 acetyl-CoA, 7 ATP, and 14 NADPH. ^[11]

This de novo synthesis pathway is quantitatively important in the liver and in skin sebaceous glands, less so in skeletal muscle (which relies primarily on circulating fatty acids). The palmitate it produces serves as the substrate from which longer-chain fatty acids are built through the ELOVL elongation system.

Malonyl-CoA in Skin: The Elongation Economy

Malonyl-CoA’s most skin-specific role is as the two-carbon donor in each step of the ELOVL elongation cycle – the mechanism by which the epidermis builds the very long-chain fatty acids (C22–C36+) that form the acyl chains of the stratum corneum’s barrier ceramides. ^[3]

The four-step ELOVL elongation cycle proceeds at the cytosolic face of the endoplasmic reticulum: condensation (ELOVL synthase adds two carbons from malonyl-CoA to the acyl chain, forming a 3-ketoacyl-CoA, with CO₂ released) → reduction (3-ketoacyl-CoA reductase) → dehydration → reduction (trans-2-enoyl-CoA reductase), producing an acyl chain two carbons longer. Each complete cycle therefore consumes one molecule of malonyl-CoA and produces one elongated acyl-CoA. To extend a C16 fatty acid to C26 requires five complete cycles – five malonyl-CoA molecules. ELOVL4’s extension into the ultralong chain range (C28–C36) required for acylceramides demands further cycles. ^[7]

This means the skin’s capacity for very long-chain ceramide construction is directly dependent on cytosolic malonyl-CoA availability from ACC1. Conditions that reduce ACC1 activity – sustained insulin suppression without adequate alternative fatty acid elongation substrate, caloric restriction affecting SREBP-1c-driven ACC1 expression, or inflammatory signals downregulating lipogenic enzyme transcription – may constrain the elongation programme and shift the ceramide profile toward shorter, less barrier-competent acyl chain lengths.

The inflammatory connection is particularly well-characterised in atopic dermatitis. A 2024 review (Blaess et al., International Journal of Molecular Sciences) confirmed that decreased ultra-long-chain and very long-chain ceramides in atopic skin result from impaired ELOVL elongation – with ELOVL6 activity particularly vulnerable to NADPH depletion under oxidative inflammatory stress. ^[3] Separately, IL-13 has been shown to directly suppress ELOVL3 and ELOVL6 expression through STAT6 signalling, the same pathway described in the Free Fatty Acids entity. ^[2]

The malonyl-CoA connection here is upstream: if ACC1 activity is also reduced (by AMPK activation under inflammatory stress, or by reduced insulin signalling), the substrate supply for whatever ELOVL capacity remains is additionally constrained. The ceramide deficit in atopic skin therefore has at least two parallel upstream failures: reduced ELOVL enzyme expression (the enzyme problem) and potentially reduced malonyl-CoA availability from ACC1 suppression (the substrate problem). These are not alternatives – both can operate simultaneously.

Degradation: Malonyl-CoA Decarboxylase and the ACC/MCD Balance

Steady-state malonyl-CoA concentration reflects the balance between ACC-mediated synthesis and degradation by malonyl-CoA decarboxylase (MCD), which catalyses the reverse reaction: malonyl-CoA → acetyl-CoA + CO₂. MCD is expressed in heart, skeletal muscle, and liver, and its activity is particularly important in cardiac muscle, where oscillating malonyl-CoA levels during varying workloads are a key part of the heart’s fuel-switching capacity. ^[9]

Early studies proposed that AMPK activated MCD directly through phosphorylation, which would give AMPK a two-pronged mechanism for reducing malonyl-CoA: inhibiting ACC (reducing synthesis) and activating MCD (increasing degradation). However, an MRC study (Saggerson group) using recombinant MCD and immunoprecipitated MCD from skeletal muscle confirmed that MCD is not an AMPK substrate – the kinase does not phosphorylate it in vitro or in fast-twitch muscle. The principal mechanism by which AMPK lowers malonyl-CoA is through ACC inactivation alone. MCD activity can be upregulated by PPAR-α and PPAR-δ transcriptionally – consistent with MCD’s role in supporting fat oxidation in fasted or lipid-rich metabolic states – but the acute AMPK→malonyl-CoA axis operates via ACC. ^[4]

This matters for precision: interventions that activate AMPK (exercise, caloric restriction, metformin, certain polyphenols) lower malonyl-CoA primarily by suppressing ACC2 activity, reducing the ACC2-derived pool that inhibits CPT-1. They do not acutely upregulate MCD to degrade existing malonyl-CoA; the fall in malonyl-CoA is driven by slowed production, not accelerated destruction.

AMPK: The Master Switch on the ACC/Malonyl-CoA Axis

AMPK (AMP-activated protein kinase) phosphorylates and inactivates both ACC1 (at Ser79) and ACC2 (at Ser221), reducing malonyl-CoA production from both isoforms simultaneously. It is activated by rising AMP concentrations – the energetic signature of active muscle contraction, glucose deprivation, or mitochondrial stress – and acts as the cell’s energy deficit sensor. When energy demand exceeds supply: AMP rises → AMPK activates → ACC1 and ACC2 phosphorylated and inactivated → malonyl-CoA falls → CPT-1 de-inhibited → fat oxidation rises (via ACC2 pool) and de novo lipogenesis slows (via ACC1 pool). ^[8]

This is the molecular mechanism by which aerobic exercise acutely increases fat oxidation in skeletal muscle. It also explains the insulin-sensitising effect of metformin at the cellular level: by inhibiting mitochondrial complex I, metformin raises the AMP/ATP ratio, activates AMPK, reduces ACC2 activity and malonyl-CoA, and de-inhibits CPT-1 – independently of changes in plasma glucose or insulin. The adiponectin/AMPK axis described in the CPT-1 entity operates through the same downstream mechanism: adiponectin → AMPK → ACC inhibition → malonyl-CoA reduction → CPT-1 de-inhibited.

The AMPK/ACC/malonyl-CoA axis is the point of convergence for nearly every physiological and pharmacological intervention that improves metabolic flexibility: exercise, carbohydrate restriction, intermittent fasting, and several pharmaceutical approaches all ultimately lower malonyl-CoA through this pathway. They are not different mechanisms – they are different inputs into the same molecular regulatory node.

Lysine Malonylation: An Emerging Regulatory Layer

A developing area of malonyl-CoA biology concerns its capacity to donate malonyl groups to lysine residues on proteins, in a post-translational modification termed lysine malonylation. The deacylase SIRT5 (a mitochondria-localised sirtuin) is the primary enzyme removing malonyl marks from proteins, suggesting active regulation rather than passive chemical modification. ^[12]

Malonylated proteins have been identified in liver, heart, and skeletal muscle, where SIRT5 activity correlates with metabolic state. The functional consequences of protein malonylation are still being characterised; early evidence suggests it may modulate enzyme activities involved in glycolysis and the urea cycle, adding a layer of metabolic feedback beyond the direct CPT-1 and FAS roles. The significance for skin biology is not established, but SIRT5 expression in keratinocytes has been documented; whether fluctuating malonyl-CoA levels in metabolically stressed skin affect keratinocyte protein malonylation is an open question. This is flagged as an emerging area rather than established biology.